JCU Connect Partner with us Our Technologies Novel Drug Targets & Cell Line for Hepatocellular Carcinoma
Novel Drug Targets & Cell Line for Hepatocellular Carcinoma
- Aboriginals and Torres Strait Islanders in Marine Science
- Courses
- Future Students
- Current Students
- Research and Teaching
- Partners and Community
- About JCU
- Reputation and Experience
- Celebrating 50 Years
- Academy
- ALTAR
- Anton Breinl Research Centre
- Agriculture Technology and Adoption Centre
- Living on Campus
- Advanced Prawn Breeding Research Hub
- Advanced Analytical Centre
- Applying to JCU
- Alumni
- AMHHEC
- JCU Aquaculture Solutions
- AusAsian Mental Health Research Group
- ARCSTA
- Area 61
- Association of Australian University Secretaries
- Australian/NZ Students
- Australian Lions Stinger Research
- Boating and Diving
- JCU-CSIRO Partnership
- Employability Edge
- Career Ready Plan
- Australian Tropical Herbarium
- Careers at JCU
- Careers and Employability
- Australian Quantum & Classical Transport Physics Group
- Centre for Tropical Bioinformatics and Molecular Biology
- CITBA
- Chancellery
- CMT
- CASE
- College of Business, Law and Governance
- College of Healthcare Sciences
- WHOCC for N&M Education and Research
- College of Medicine and Dentistry
- College of Science and Engineering
- CPHMVS
- COVID-19 Advice
- Centre for Disaster Solutions
- CSTFA
- Cyclone Testing Station
- The Centre for Disaster Studies
- Daintree Rainforest Observatory
- Diploma of Higher Education
- Discover Nature at JCU
- Research Division
- Services and Resources Division
- Education Division
- Division of Tropical Environments and Societies
- Division of Tropical Health and Medicine
- Economic Geology Research Centre
- Elite Athletes
- eResearch
- ERC
- Estate
- Financial and Business Services Office
- Fletcherview
- Foundation for Australian Literary Studies
- Gender Equity Action and Research
- GetReady4Uni
- Give to JCU
- Governance
- Information for JCU Cairns Graduates
- Graduate Research School
- Graduation
- Indigenous Education and Research Centre
- Indigenous Engagement
- Indigenous Legal Needs Project
- Inherent Requirements
- IsoTropics Geochemistry Lab
- IT Services
- International Schools
- International Students
-
JCU Connect
- About JCU Connect
- Partner with us
- Innovate with us
- Research Grants, Tenders and Funding
- Ethics and Research Integrity
- Research Contracts
- Research Performance Reporting and Analytics
- Discover our Research and Testing Facilities
- JCU Ideas Lab
- Find an Expert
- Contact JCU Connect
- FAQs and Fact Sheets
- JCU Eduquarium
- JCU Events
- JCU Global Experience
- JCU Ideas Lab
- JCU Job Ready
- JCU Motorsports
- JCU Prizes
- JCU Sport
- JCU Turtle Health Research
- Language and Culture Research Centre
- CEE
- LearnJCU
- Library
- Mabo Decision: 30 years on
- MARF
- Marine Geophysics Laboratory
- New students
- Off-Campus Students
- Office of the Vice Chancellor and President
- Virtual Open Day
- Orpheus
- Outstanding Alumni Awards
- Parents and Partners
- Pathways to university
- Planning for your future
- Placements
- Policy
- PAHL
- Publications
- Professional Experience Placement
- Queensland Research Centre for Peripheral Vascular Disease
- Rapid Assessment Unit
- RDIM
- Researcher Development Portal
- Safety and Wellbeing
- Scholarships
- Contextual Science for Tropical Coastal Ecosystems
- Staff
- State of the Tropics
- Strategic Procurement
- Student Equity and Wellbeing
- Student profiles
- SWIRLnet
- TARL
- TESS
- TREAD
- TropEco
- TQ Maths Hub
- TUDLab
- Unicare Centre and Unicampus Kids
- UAV
- VAVS Home
- Work Health and Safety
- WHOCC for Vector-borne & NTDs
- Media
- Copyright and Terms of Use
- Australian Institute of Tropical Health & Medicine
Hepatocellular carcinoma (HCC) is associated with very poor survival and is a leading cause of cancer-related deaths. HCC is rapidly growing in prevalence. New and innovative therapies for HCC are urgently required.
James Cook University have developed unique transplantable cell lines from a syngeneic model of murine HCC on the C57B/6 background. The cell lines can be used for in vitro and in vivo drug screens. As an example, we used in vitro & in vivo studies to illustrate the efficacy of a combinatorial therapy of 2 drugs: rapamycin and dasatinib (Figure 1).
Figure 1. Combination therapy of 2 drugs studied using our novel lines for HCC showing synergistic effect in in vivo studies.
Researchers have also identified 3 novel drug targets for HCC from animal model studies. Western blot confirmed the expression of the corresponding proteins in HCC cell lines & primary NASH HCCs. The genes have functions in metabolism, cell division & double strand DNA repair. We used siRNA to study effects of gene knockdown of the lead target, involved in dsDNA repair, on the activity of cisplatin (Figure 2).
Figure 2. Reduced gene expression of target gene 9 (TSV1) increased lethality of cisplatin.
- The cell lines & animal models show good similar pathology between parental & transplanted tumour.
- The drug targets are novel & can be used to develop first-in-class therapies.
- The cell lines can be used for screening drug candidates.
- The drug targets can be used for developing novel drugs and combination therapies against HCC & other cancers.
James Cook University are seeking partners for early-stage research support & co-development.
2019 goals:
- Further target validation in vitro & in vivo
- Relationship to DNA repair
- Validation with known drugs e.g. sorafenib, lenvatinib, regorafenib
- Assay development
The studies will lead to a dug discovery & development program using the novel target.
2020-22 goals:
- Optimise assays & being high-throughput screens (HTS)
- Complete HTS using compound libraries
- Conduct biochemical & cell-based tests of promising lead.
The JCU research team has extensive experience in research in metabolism, gene expression, siRNA/shRNA use, mouse models and cell biology.
Research infrastructure includes cell culture, mouse house, metabolic analysers, cell biology equipment, equipment for protein and RNA evaluation.
Seeking:
- Development partner
- Commercial partner
- Licensing